MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40674-024-00217-3

Медицинская библиотека · Current treatment options in rheumatology · 2024

Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.

Saavedra Alene A, Mueller Kevin T, Kowalski Emily N, Qian Grace, Bade Katarina J, Vanni Kathleen Mm, McDermott Gregory C, Sparks Jeffrey A

СтатьяПеревод в очереди

Аннотация

PURPOSE OF REVIEW: To summarize the current treatment landscape of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) in the context of the recent 2023 American College of Rheumatology/American College of Chest Physicians guideline for ILD treatment in systemic autoimmune rheumatic diseases.

RECENT FINDINGS: The guideline conditionally recommends mycophenolate, azathioprine, and rituximab for first-line RA-ILD therapy, with cyclophosphamide and short-term glucocorticoids as additional options. For RA-ILD progression after first line, mycophenolate, rituximab, nintedanib, tocilizumab, cyclophosphamide, and pirfenidone are conditionally recommended, while long-term glucocorticoids are conditionally recommended against. Only three randomized controlled trials (RCTs) enrolled patients with RA-ILD (total n=217). All other recommendations for RA-ILD were based on RCTs for other diseases or observational data. Antifibrotics might be particularly effective for patients with RA-ILD and the usual interstitial pneumonia pattern (RA-UIP). There is uncertainty of the utility of azathioprine and glucocorticoids in RA-UIP since these medications had worse outcomes compared to placebo in an RCT of patients with idiopathic pulmonary fibrosis. RA-ILD treatment decisions should consider articular activity, ILD activity, comorbidities, and potential for infection.

SUMMARY: We summarized the current treatment landscape for RA-ILD. Since only three RCTs included patients with RA-ILD, most guideline recommendations were conditional and based on low-quality evidence. This highlights the urgent need for additional high-quality RCT data for efficacy and safety of anti-inflammatory and antifibrotic medications for RA-ILD.

Для цитирования: Saavedra Alene A, Mueller Kevin T, Kowalski Emily N, Qian Grace, Bade Katarina J, Vanni Kathleen Mm, McDermott Gregory C, Sparks Jeffrey A. Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.. Current treatment options in rheumatology. 2024. DOI: 10.1007/s40674-024-00217-3.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.